

Perseon Corp  
Form SC 14D9/A  
November 30, 2015

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 14D-9  
(Rule 14d-101)  
Solicitation/Recommendation Statement  
Under Section 14(d)(4) of the Securities Exchange Act of 1934  
Amendment No. 1

PERSEON CORPORATION  
(Name of Subject Company)

PERSEON CORPORATION  
(Name of Persons Filing Statement)

Common Stock, par value \$0.001 per share  
Warrants to purchase common stock  
(Title of Class of Securities)

715270 203

715270 112

(CUSIP Number of Class of Securities)

Clinton E. Carnell Jr.

President

Perseon Corporation

460 West 50 North

Salt Lake City, UT 84101

(801) 972-5555

(Name, address and telephone numbers of person authorized to receive notice and communications  
on behalf of the persons filing statement)

With copies to:

Nolan S. Taylor

David Marx

Dorsey & Whitney LLP

Edgar Filing: Perseon Corp - Form SC 14D9/A

136 South Main Street, Suite 1000  
Salt Lake City, Utah 84101-1685  
(801) 933-7363

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

---

This Amendment No. 1 ("Amendment No. 1") amends and supplements Item 9 in the Solicitation/Recommendation Statement on Schedule 14D-9 filed by Perseon Corporation (the "Company") with the Securities and Exchange Commission on November 5, 2015 (as amended and supplemented from time to time, the "Schedule 14D-9"). The Schedule 14D-9 relates to the tender offer (the "Offer") by Galil Merger Sub, Inc. ("Merger Sub"), a subsidiary of Galil Medical Inc. ("Galil"), and Galil is a direct wholly owned subsidiary of Galil Medical Ltd. ("Israeli Parent" and, together with Merger Sub and Galil, the "Offeror Group"), to purchase all of the Company's outstanding common stock, par value \$0.001 per share (the "Shares") for \$1.00 per Share, and all of the warrants to purchase Shares (the "Public Warrants"), which Public Warrants were issued pursuant to the prospectus dated July 29, 2015 and are publicly traded on The Nasdaq Capital Market under the symbol "PRSNW" for \$0.02 per Public Warrant, upon the terms and subject to the conditions set forth in the Offer to Purchase by the Offeror Group dated November 5, 2015, and in the related Letter of Transmittal, as each may be amended or supplemented from time to time. The Offer is currently scheduled to expire at 11:59 p.m., New York City time, at the end of the day on December 7, 2015.

Except as otherwise set forth below, the information set forth in the Schedule 14D-9 remains unchanged and is incorporated herein by reference as relevant to the items in this Amendment No. 1. Capitalized terms used but not otherwise defined herein have the meanings ascribed to such terms in the Schedule 14D-9.

Item 9. Exhibits.

Item 9 of the Schedule 14D-9 is hereby amended and supplemented by adding to the list of Exhibits immediately following the Exhibit listed as Exhibit (a)(5)(A) the following Exhibit:

(a)(5)(B) Press Release dated November 30, 2015. Incorporated by reference to Exhibit 99.1 to the Company's Form 8-K filed November 30, 2015.

---

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 30, 2015

**PERSEON CORPORATION**

By: /s/ Clinton E. Carnell Jr.

Name: Clinton E. Carnell Jr.

Title: President and Chief Executive Officer  
Principal Executive Officer

---